Caplin Point clears INVIMA inspection at Puducherry injectables facility

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

CAPLIPOINT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.1%Reaction day

₹1958.00

prior close

₹1965.00

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.4%-0.4% vs market

Pharmaceuticals peers, median of 155sector-0.1%+0.0% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Smallcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.7

15m

-0.7

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.1+0.4-0.4-0.1+0.0

Next day

-0.7-0.4-0.2-0.6-0.0

-3.0-1.1-1.8-1.3-1.7

-2.2-1.2-0.9-1.4-0.8

-1.4+0.1-1.5-0.6-0.8

+0.3+1.0-0.8-0.0+0.3

+0.4+1.5-1.1-0.1+0.5

15d

-6.5+2.4-8.9+0.7-7.2

-7.0-1.2-5.8-2.7-4.3

-12.3-2.5-9.7-4.7-7.6

-16.6-9.7-6.9-10.9-5.8

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Caplin Point Laboratories' injectables facility in Puducherry successfully cleared an inspection by INVIMA-Colombia, the Colombian health regulator, conducted between December 8 and 12, 2025. This is an important milestone in the company's product strategy for expanding into the larger Latin American market for specialty injectable products and complements its already INVIMA-approved Softgel section at the same site.

Likely market impact

Positive regulatory milestone supporting Latin America expansion for injectables, potentially enabling future product approvals and revenue growth in the region.